title: Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
abstract: Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the industrialised world. While treatment options for advanced AMD have been rather limited until recently, the introduction of intravitreal injections of anti-angiogenic agents appears to be a promising and revolutionary mode of treatment for this blinding disease. Vascular endothelial growth factor (VEGF) appears to play a pivotal role in the pathogenesis of choroidal neovascularisation, one of the cornerstones of advanced AMD. Pegaptanib, the first anti-VEGF treatment approved for AMD patients, is a VEGF-neutralising aptamer that specifically inhibits one isoform of VEGF (VEGF-165). Although evidence suggested that pegaptanib was superior to previous treatment options, results with this agent were still unsatisfactory. Ranibizumab is a humanised anti-VEGF monoclonal antibody fragment that inhibits all isotypes of VEGF. This new drug has demonstrated a high efficacy profile in terms of inhibiting disease progression and even improving visual acuity. Bevacizumab is a full-length anti-VEGF antibody that was originally approved for use in metastatic colon cancer and is under investigation as a low-cost off-label alternative for patients with AMD. There is growing evidence that this drug may be an effective and safe alternative to the more expensive ranibizumab, although prospective multicentre trials are required to fully investigate this issue. Undoubtedly, the concept of directly injecting anti-VEGF drugs into the vitreal cavity brings new hope to many AMD patients.
authors: Ophthalmology Department, Tel-Aviv Sourasky Medical Centre, Tel-Aviv University, Tel-Aviv, Israel. mwaisbourd@hotmail.com
authors: Michael
authors: M
authors: Waisbourd
authors: Anat
authors: A
authors: Loewenstein
authors: Michaella
authors: M
authors: Goldstein
authors: Igal
authors: I
authors: Leibovitch
mesh_terms: D000375:Aging; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D016503:Drug Delivery Systems; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab
references: Retina. 2006 May-Jun;26(5):495-511
references: 16770255
references: Retina. 2006 Mar;26(3):270-4
references: 16508425
references: Br J Ophthalmol. 2006 Sep;90(9):1207-8
references: 16929069
references: Br J Ophthalmol. 2006 Jul;90(7):922
references: 16782958
references: Ophthalmology. 2006 Nov;113(11):2002.e1-12
references: 17027972
references: Invest Ophthalmol Vis Sci. 2003 Jan;44(1):290-9
references: 12506087
references: Br J Ophthalmol. 1997 Feb;81(2):154-62
references: 9059252
references: Surv Ophthalmol. 2006 Jul-Aug;51(4):316-63
references: 16818082
references: Ophthalmology. 2005 Jun;112(6):1035-47
references: 15936441
references: Toxicol Pathol. 1999 Sep-Oct;27(5):536-44
references: 10528633
references: N Engl J Med. 2006 Oct 5;355(14 ):1432-44
references: 17021319
references: N Engl J Med. 2006 Oct 5;355(14):1409-12
references: 17021315
references: Ophthalmology. 2006 Mar;113(3):501
references: 16513466
references: Gene Ther. 2005 Oct;12 Suppl 1:S159-69
references: 16231050
references: Am J Ophthalmol. 2006 Apr;141(4):752-4
references: 16564819
references: N Engl J Med. 1971 Nov 18;285(21):1182-6
references: 4938153
references: Retina. 2005 Dec;25(8):1065-84
references: 16340538
references: Retina. 2006 Jul-Aug;26(6 Suppl):S17-20
references: 16832293
references: Arch Ophthalmol. 2006 Nov;124(11):1532-42
references: 17101999
references: Arch Ophthalmol. 2006 Oct;124(10 ):1478-9
references: 17030717
references: Ophthalmology. 2006 Apr;113(4):633.e1-4
references: 16483659
references: Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4569-78
references: 17003454
references: Nat Rev Neurosci. 2006 Nov;7(11):860-72
references: 17033682
references: JAMA. 2004 Apr 21;291(15):1900-1
references: 15108691
references: Front Biosci. 1999 Feb 01;4:D141-52
references: 9924144
references: Arch Ophthalmol. 2004 Apr;122(4):564-72
references: 15078675
references: Clin Ther. 2006 Jan;28(1):36-44
references: 16490578
references: Arch Ophthalmol. 2006 May;124(5):660-4
references: 16682587
references: Ophthalmology. 2006 Apr;113(4):623.e1
references: 16581423
references: Arch Ophthalmol. 2002 Mar;120(3):338-46
references: 11879138
references: Exp Nephrol. 1998 Nov-Dec;6(6):480-7
references: 9807017
references: Retina. 2006 Oct;26(8):859-70
references: 17031284
references: N Engl J Med. 2004 Dec 30;351(27):2805-16
references: 15625332
references: Br J Ophthalmol. 2006 Sep;90(9):1188-96
references: 16929063
references: Retina. 2006 Mar;26(3):262-9
references: 16508424
references: Ophthalmology. 2006 Sep;113(9):1508.e1-25
references: 16828500
references: JAMA. 2005 Mar 23;293(12 ):1509-13
references: 15784876
references: Invest Ophthalmol Vis Sci. 2006 Jan;47(1):357-63
references: 16384985
references: Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3186-93
references: 12824270
references: N Engl J Med. 2006 Oct 5;355(14):1419-31
references: 17021318
references: J Cell Sci. 2001 Mar;114(Pt 5):853-65
references: 11181169
references: Retina. 2005 Oct-Nov;25(7):815-27
references: 16205558
references: Arch Ophthalmol. 1991 Aug;109(8):1060-1
references: 1867539
references: Pharmacol Rev. 2004 Dec;56(4):549-80
references: 15602010
references: Am J Ophthalmol. 2006 Jul;142(1):1-9
references: 16815245
references: Graefes Arch Clin Exp Ophthalmol. 2007 May;245(5):651-5
references: 17006681
references: Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33
references: 15671306
references: Retina. 2006 Oct;26(8):871-6
references: 17031285
references: Ophthalmology. 1992 Jun;99(6):933-43
references: 1630784
references: Am J Ophthalmol. 2006 Jul;142(1):141-3
references: 16815262
references: Ophthalmology. 2005 Apr;112(4):531-2
references: 15808239
references: Acta Ophthalmol Scand. 2006 Oct;84(5):713-4
references: 16965511
references: Adv Drug Deliv Rev. 2005 Dec 13;57(14):2063-79
references: 16310884
references: N Engl J Med. 2006 Oct 5;355(14):1474-85
references: 17021323
references: Curr Opin Mol Ther. 2003 Dec;5(6):673-9
references: 14755895
references: Pharm Res. 2000 Dec;17(12):1503-10
references: 11303960
references: Br J Ophthalmol. 2006 Nov;90(11):1344-9
references: 16854824
references: Ophthalmol Clin North Am. 2006 Sep;19(3):361-72
references: 16935211
references: Ophthalmology. 2005 Jun;112(6):1048-53
references: 15885778
references: Retina. 2006 Apr;26(4):383-90
references: 16603955
references: Microvasc Res. 2002 Jul;64(1):162-9
references: 12074642
references: Ophthalmology. 2006 Mar;113(3):363-372.e5
references: 16458968
references: Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5
references: 16156152
references: Retina. 2002 Apr;22(2):143-52
references: 11927845
references: Arch Ophthalmol. 2001 Oct;119(10):1417-36
references: 11594942
references: Retina. 2006 Oct;26(8):877-81
references: 17031286
references: Arch Ophthalmol. 2005 Apr;123(4):509-16
references: 15824225
references: Retina. 2006 Mar;26(3):257-61
references: 16508423